{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:43Z","timestamp":1792787983310,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Narodowa Agencja Wymiany Akademickiej","doi-asserted-by":"publisher","award":["PPN\/STA\/2021\/1\/00027"],"award-info":[{"award-number":["PPN\/STA\/2021\/1\/00027"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Institute of Oncology, Gliwice","award":["SN\/MGW7\/2023"],"award-info":[{"award-number":["SN\/MGW7\/2023"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG\/JA-2461\/7-1 and CRC TRR332 project A05"],"award-info":[{"award-number":["DFG\/JA-2461\/7-1 and CRC TRR332 project A05"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2019\/35\/O\/NZ5\/02600"],"award-info":[{"award-number":["2019\/35\/O\/NZ5\/02600"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Natural killer (NK) cells are at the forefront of the fight against infections and cancer, where they recognize targets through a system of inhibitory and activating ligands expressed on monitored cells. The transcriptional regulation of such ligands in tumors remains poorly understood. Our previous transcriptomic studies suggest that the tumor suppressor p53 may upregulate key NK-activating ligands, including SLAM family member 7 (\n                      <jats:italic>SLAMF7<\/jats:italic>\n                      ) and natural killer cell cytotoxicity receptor 3 ligand 1 (\n                      <jats:italic>NCR3LG1<\/jats:italic>\n                      ). Herein, we aimed to validate the functional role of this regulatory axis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Isogenic p53-proficient and p53-deficient cell lines from diverse cancer types (A549, NCI-H460, U-2 OS) were used to examine p53-dependent regulation of\n                      <jats:italic>SLAMF7<\/jats:italic>\n                      and\n                      <jats:italic>NCR3LG1.<\/jats:italic>\n                      Luciferase reporter assays assessed putative p53-responsive enhancer elements, with pharmacological activation of p53 achieved using DNA-damaging agents (actinomycin D and camptothecin) and the MDM2 proto-oncogene inhibitor nutlin-3a. The functional impact of NK cell-mediated cytotoxicity was assessed using primary human NK cells and the NK-92 cell line.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pharmacological activation of p53 using camptothecin or combined actinomycin D and nutlin-3a strongly induced\n                      <jats:italic>SLAMF7<\/jats:italic>\n                      and\n                      <jats:italic>NCR3LG1<\/jats:italic>\n                      expression in p53-proficient, but not p53-deficient, cancer cell lines. The SLAMF7 protein, typically expressed only in immune cells, was strongly induced in epithelial and mesenchymal cancer models following p53 activation. Paclitaxel upregulated SLAMF7 independently of p53, suggesting an alternative pathway of induction. Notably, dual treatment with actinomycin D and nutlin-3a induced the secretion of soluble SLAMF7. Also,\n                      <jats:italic>NCR3LG1<\/jats:italic>\n                      was strongly upregulated in a p53-dependent fashion. The cloned fragments of these genes, located in regions suggestive of enhancer activity, conferred p53 responsiveness to the reporter gene. Functionally, dual p53 activation by actinomycin D and nutlin-3a significantly increased tumor cell susceptibility to cytolysis by both primary human NK cells and the NK-92 cell line.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SLAMF7 expression can be induced in non-hematological cancers by p53-dependent and p53-independent mechanisms following exposure to anticancer agents. Given that SLAMF7 is a clinically validated target of the monoclonal antibody Elotuzumab in multiple myeloma, its drug-inducible expression in solid tumors is of particular interest. This finding may support the development of novel therapeutic strategies incorporating SLAMF7-targeting antibodies in p53-competent non-hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-026-02772-9","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T08:35:13Z","timestamp":1772699713000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The p53 tumor suppressor modulates the expression of proteins that control natural killer cell activity"],"prefix":"10.1186","volume":"24","author":[{"given":"Agnieszka","family":"B\u0119dzi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Gdowicz-K\u0142osok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Krze\u015bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"\u0141asut-Szyszka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Zeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Chwieduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Smagur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Jablonska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Rusin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2772_CR1","doi-asserted-by":"publisher","unstructured":"Liu Y, Stockwell BR, Jiang X, Gu W. p53-regulated non-apoptotic cell death pathways and their relevance in cancer and other diseases. Nat Rev Mol Cell Biol. 2025 Apr 9. https:\/\/doi.org\/10.1038\/s41580-025-00842-3. Epub ahead of print. PMID: 40204927.","DOI":"10.1038\/s41580-025-00842-3"},{"issue":"9\u201310","key":"2772_CR2","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10495-024-02000-0","volume":"29","author":"B \u0141asut-Szyszka","year":"2024","unstructured":"\u0141asut-Szyszka B, Gdowicz-K\u0142osok A, Krze\u015bniak M, G\u0142owala-Kosi\u0144ska M, B\u0119dzi\u0144ska A, Rusin M. Strong activation of p53 by actinomycin D and nutlin-3a overcomes the resistance of cancer cells to the pro-apoptotic activity of the FAS ligand. Apoptosis. 2024;29(9\u201310):1515\u201328. https:\/\/doi.org\/10.1007\/s10495-024-02000-0. Epub 2024 Jul 28. PMID: 39068622; PMCID: PMC11416401.","journal-title":"Apoptosis"},{"key":"2772_CR3","doi-asserted-by":"publisher","unstructured":"\u00c1lvarez-Carrasco P, Maldonado-Bernal C. The innate defenders: a review of natural killer cell immunotherapies in cancer. Front Immunol. 2024;15:1482807. https:\/\/doi.org\/10.3389\/fimmu.2024.1482807. PMID: 39763648; PMCID: PMC11700995.","DOI":"10.3389\/fimmu.2024.1482807"},{"key":"2772_CR4","doi-asserted-by":"publisher","unstructured":"Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, Szekely L, K\u00e4rre K, Carbone E, Selivanova G. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle. 2011;10(19):3346-58. https:\/\/doi.org\/10.4161\/cc.10.19.17630. Epub 2011 Oct 1. PMID: 21941086.","DOI":"10.4161\/cc.10.19.17630"},{"issue":"18","key":"2772_CR5","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1158\/0008-5472.CAN-10-3211","volume":"71","author":"S Textor","year":"2011","unstructured":"Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011;71(18):5998\u20136009. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-3211. Epub 2011 Jul 15. PMID: 21764762.","journal-title":"Cancer Res"},{"issue":"20","key":"2772_CR6","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.3390\/ijms222011072","volume":"22","author":"B \u0141asut-Szyszka","year":"2021","unstructured":"\u0141asut-Szyszka B, Ma\u0142achowska B, Gdowicz-K\u0142osok A, Krze\u015bniak M, G\u0142owala-Kosi\u0144ska M, Zajkowicz A, Rusin M. Transcriptome Analysis of Cells Exposed to Actinomycin D and Nutlin-3a Reveals New Candidate p53-Target Genes and Indicates That CHIR-98014 Is an Important Inhibitor of p53 Activity. Int J Mol Sci. 2021;22(20):11072. https:\/\/doi.org\/10.3390\/ijms222011072. PMID: 34681730; PMCID: PMC8538697.","journal-title":"Int J Mol Sci"},{"key":"2772_CR7","doi-asserted-by":"publisher","first-page":"110946","DOI":"10.1016\/j.cbi.2024.110946","volume":"392","author":"B \u0141asut-Szyszka","year":"2024","unstructured":"\u0141asut-Szyszka B, Gdowicz-K\u0142osok A, Ma\u0142achowska B, Krze\u015bniak M, B\u0119dzi\u0144ska A, Gawin M, Pietrowska M, Rusin M. Transcriptomic and proteomic study of cancer cell lines exposed to actinomycin D and nutlin-3a reveals numerous, novel candidates for p53-regulated genes. Chem Biol Interact. 2024;392:110946. Epub 2024 Mar 7. PMID: 38460933.","journal-title":"Chem Biol Interact"},{"key":"2772_CR8","doi-asserted-by":"publisher","unstructured":"Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1\u20132):1\u20138. https:\/\/doi.org\/10.1016\/s0161-5890(02)00094-9. PMID: 12213321.","DOI":"10.1016\/s0161-5890(02)00094-9"},{"issue":"1","key":"2772_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/eji.202149406","volume":"52","author":"A Gutierrez-Guerrero","year":"2022","unstructured":"Gutierrez-Guerrero A, Mancilla-Herrera I, Maravillas-Montero JL, Martinez-Duncker I, Veillette A, Cruz-Munoz ME. SLAMF7 selectively favors degranulation to promote cytotoxicity in human NK cells. Eur J Immunol. 2022;52(1):62\u201374. https:\/\/doi.org\/10.1002\/eji.202149406. Epub 2021 Nov 14. PMID: 34693521.","journal-title":"Eur J Immunol"},{"issue":"7","key":"2772_CR10","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/jem.20090681","volume":"206","author":"CS Brandt","year":"2009","unstructured":"Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, Moretta A, West R, Xu W, Vivier E, Levin SD. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495\u2013503. https:\/\/doi.org\/10.1084\/jem.20090681. Epub 2009 Jun 15. PMID: 19528259; PMCID: PMC2715080.","journal-title":"J Exp Med"},{"issue":"19","key":"2772_CR11","doi-asserted-by":"publisher","first-page":"10326","DOI":"10.3390\/ijms251910326","volume":"25","author":"S Lee","year":"2024","unstructured":"Lee S, Kim JH, Jang IH, Jo S, Lee SY, Oh SC, Kim SM, Kong L, Ko J, Kim TD. Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies. Int J Mol Sci. 2024;25(19):10326. https:\/\/doi.org\/10.3390\/ijms251910326. PMID: 39408655; PMCID: PMC11476788.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2772_CR12","first-page":"4721","volume":"12","author":"SH Wang","year":"2022","unstructured":"Wang SH, Chou WC, Huang HC, Lee TA, Hsiao TC, Wang LH, Huang KB, Kuo CT, Chao CH, Chang SJ, Hsu JM, Weng J, Ren N, Li FA, Lai YJ, Zhou C, Hung MC, Li CW. Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis. Am J Cancer Res. 2022;12(10):4721\u201336. PMID: 36381324; PMCID: PMC9641385.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"2772_CR13","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.3390\/curroncol30090573","volume":"30","author":"E Chu","year":"2023","unstructured":"Chu E, Wu J, Kang SS, Kang Y. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments. Curr Oncol. 2023;30(9):7891\u2013903. https:\/\/doi.org\/10.3390\/curroncol30090573. PMID: 37754488; PMCID: PMC10529721.","journal-title":"Curr Oncol"},{"issue":"4","key":"2772_CR14","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329\u201337. https:\/\/doi.org\/10.1182\/blood-2007-08-107292. Epub 2007 Sep 28. PMID: 17906076; PMCID: PMC2515112.","journal-title":"Blood"},{"issue":"4","key":"2772_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1208\/s12248-016-9912-3","volume":"18","author":"J Postelnek","year":"2016","unstructured":"Postelnek J, Neely RJ, Robbins MD, Gleason CR, Peterson JE, Piccoli SP. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab. AAPS J. 2016;18(4):989\u201399. https:\/\/doi.org\/10.1208\/s12248-016-9912-3. Epub 2016 Apr 26. PMID: 27116021.","journal-title":"AAPS J"},{"issue":"9","key":"2772_CR16","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/j.cellsig.2015.05.005","volume":"27","author":"A Zajkowicz","year":"2015","unstructured":"Zajkowicz A, Gdowicz-K\u0142osok A, Krze\u015bniak M, \u015aciegli\u0144ska D, Rusin M. Actinomycin D and nutlin-3a synergistically promote phosphorylation of p53 on serine 46 in cancer cell lines of different origin. Cell Signal. 2015;27(9):1677\u201387. https:\/\/doi.org\/10.1016\/j.cellsig.2015.05.005. Epub 2015 May 16. PMID: 25989210.","journal-title":"Cell Signal"},{"key":"2772_CR17","doi-asserted-by":"crossref","unstructured":"Oki S, Ohta T, Shioi G, Hatanaka H, Ogasawara O, Okuda Y, Kawaji H, Nakaki R, Sese J, Meno C. ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data. EMBO Rep. 2018 Dec;19(12):e46255. doi: 10.15252\/embr.201846255. Epub 2018 Nov 9. PMID: 30413482; PMCID: PMC6280645.","DOI":"10.15252\/embr.201846255"},{"issue":"8","key":"2772_CR18","doi-asserted-by":"publisher","first-page":"e1003726","DOI":"10.1371\/journal.pgen.1003726","volume":"9","author":"K Schlereth","year":"2013","unstructured":"Schlereth K, Heyl C, Krampitz AM, Mernberger M, Finkernagel F, Scharfe M, Jarek M, Leich E, Rosenwald A, Stiewe T. Characterization of the p53 cistrome\u2013DNA binding cooperativity dissects p53\u2019s tumor suppressor functions. PLoS Genet. 2013;9(8):e1003726. https:\/\/doi.org\/10.1371\/journal.pgen.1003726. Epub 2013 Aug 15. PMID: 23966881; PMCID: PMC3744428.","journal-title":"PLoS Genet"},{"issue":"1","key":"2772_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1186\/s12864-015-1643-9","volume":"16","author":"T Tebaldi","year":"2015","unstructured":"Tebaldi T, Zaccara S, Alessandrini F, Bisio A, Ciribilli Y, Inga A. Whole-genome cartography of p53 response elements ranked on transactivation potential. BMC Genomics. 2015;16(1):464. https:\/\/doi.org\/10.1186\/s12864-015-1643-9. PMID: 26081755; PMCID: PMC4470028.","journal-title":"BMC Genomics"},{"issue":"7295","key":"2772_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature09033","volume":"465","author":"TK Kim","year":"2010","unstructured":"Kim TK, Hemberg M, Gray JM, Costa AM, Bear DM, Wu J, Harmin DA, Laptewicz M, Barbara-Haley K, Kuersten S, Markenscoff-Papadimitriou E, Kuhl D, Bito H, Worley PF, Kreiman G, Greenberg ME. Widespread transcription at neuronal activity-regulated enhancers. Nature. 2010;465(7295):182\u20137. https:\/\/doi.org\/10.1038\/nature09033. Epub 2010 Apr 14. PMID: 20393465; PMCID: PMC3020079.","journal-title":"Nature"},{"issue":"3","key":"2772_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molcel.2012.11.021","volume":"49","author":"CA Melo","year":"2013","unstructured":"Melo CA, Drost J, Wijchers PJ, van de Werken H, de Wit E, Oude Vrielink JA, Elkon R, Melo SA, L\u00e9veill\u00e9 N, Kalluri R, de Laat W, Agami R. eRNAs are required for p53-dependent enhancer activity and gene transcription. Mol Cell. 2013;49(3):524\u201335. Epub 2012 Dec 27. PMID: 23273978.","journal-title":"Mol Cell"},{"issue":"1","key":"2772_CR22","doi-asserted-by":"publisher","first-page":"zcac009","DOI":"10.1093\/narcan\/zcac009","volume":"4","author":"M Fischer","year":"2022","unstructured":"Fischer M, Schwarz R, Riege K, DeCaprio JA, Hoffmann S. TargetGeneReg 2.0: a comprehensive web-atlas for p53, p63, and cell cycle-dependent gene regulation. NAR Cancer. 2022;4(1):zcac009. https:\/\/doi.org\/10.1093\/narcan\/zcac009. PMID: 35350773; PMCID: PMC8946727.","journal-title":"NAR Cancer"},{"issue":"5","key":"2772_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","volume":"25","author":"H Klingemann","year":"2023","unstructured":"Klingemann H. The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer. Cytotherapy. 2023;25(5):451\u20137. https:\/\/doi.org\/10.1016\/j.jcyt.2022.12.003. Epub 2023 Jan 6. PMID: 36610812.","journal-title":"Cytotherapy"},{"key":"2772_CR24","doi-asserted-by":"publisher","unstructured":"Renner WA, Jordan M, Eppenberger HM, Leist C. Cell-cell adhesion and aggregation: Influence on the growth behavior of CHO cells. Biotechnol Bioeng. 1993;41(2):188\u2009\u2013\u200993. https:\/\/doi.org\/10.1002\/bit.260410204. PMID: 18609537.","DOI":"10.1002\/bit.260410204"},{"key":"2772_CR25","doi-asserted-by":"publisher","unstructured":"Zhu Y, Huang B, Shi J. Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target. Oncotarget. 2016;7(30):47163\u201347172. https:\/\/doi.org\/10.18632\/oncotarget.9980. PMID: 27323411.","DOI":"10.18632\/oncotarget.9980"},{"issue":"4","key":"2772_CR26","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.3892\/ol.2017.6767","volume":"14","author":"H Zhou","year":"2017","unstructured":"Zhou H, Cui X, Yuan H, Zhang B, Meng C, Zhao D. Effects of distinct drugs on gene transcription in an osteosarcoma cell line. Oncol Lett. 2017;14(4):4694\u2013700. https:\/\/doi.org\/10.3892\/ol.2017.6767. Epub 2017 Aug 18. PMID: 29085469; PMCID: PMC5649527.","journal-title":"Oncol Lett"},{"issue":"1","key":"2772_CR27","doi-asserted-by":"publisher","first-page":"114516","DOI":"10.1016\/j.yexcr.2025.114516","volume":"447","author":"FMA Altalbawy","year":"2025","unstructured":"Altalbawy FMA, Babamuradova Z, Baldaniya L, Singh A, Singh KU, Ballal S, Sabarivani A, Sead FF, Alam R, Alshahrani MY. The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders. Exp Cell Res. 2025;447(1):114516. Epub 2025 Mar 10. PMID: 40073958.","journal-title":"Exp Cell Res"},{"issue":"1","key":"2772_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-016-0284-z","volume":"9","author":"Y Wang","year":"2016","unstructured":"Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):55. https:\/\/doi.org\/10.1186\/s13045-016-0284-z. PMID: 27417553; PMCID: PMC4946088.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2772_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","volume":"34","author":"J Kikuchi","year":"2020","unstructured":"Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, Izumi T, Yasui H, Suzuki A, Furukawa Y. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020;34(1):180\u201395. https:\/\/doi.org\/10.1038\/s41375-019-0525-6. Epub 2019 Jul 29. PMID: 31358854.","journal-title":"Leukemia"},{"issue":"11","key":"2772_CR30","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1038\/s41375-020-0860-7","volume":"34","author":"A Suzuki","year":"2020","unstructured":"Suzuki A, Kakugawa S, Miyoshi M, Hori M, Suzuki K, Furukawa Y, Ohta K. Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy. Leukemia. 2020;34(11):3088\u201390. https:\/\/doi.org\/10.1038\/s41375-020-0860-7. Epub 2020 May 12. PMID: 32398792.","journal-title":"Leukemia"},{"issue":"78","key":"2772_CR31","doi-asserted-by":"publisher","first-page":"34784","DOI":"10.18632\/oncotarget.26196","volume":"9","author":"M Ishibashi","year":"2018","unstructured":"Ishibashi M, Soeda S, Sasaki M, Handa H, Imai Y, Tanaka N, Tanosaki S, Ito S, Odajima T, Sugimori H, Asayama T, Sunakawa M, Kaito Y, Kinoshita R, Kuribayashi Y, Onodera A, Moriya K, Tanaka J, Tsukune Y, Komatsu N, Inokuchi K, Tamura H. Clinical impact of serum soluble SLAMF7 in multiple myeloma. Oncotarget. 2018;9(78):34784\u201393. https:\/\/doi.org\/10.18632\/oncotarget.26196. PMID: 30410677; PMCID: PMC6205184.","journal-title":"Oncotarget"},{"key":"2772_CR32","doi-asserted-by":"publisher","unstructured":"Assidi M. Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer. Oncol Lett. 2022;24(6):433. https:\/\/doi.org\/10.3892\/ol.2022.13553. PMID: 36311690; PMCID: PMC9607863.","DOI":"10.3892\/ol.2022.13553"},{"issue":"6","key":"2772_CR33","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.3802\/jgo.2024.35.e79","volume":"35","author":"Y Deng","year":"2024","unstructured":"Deng Y, Zhang L, Dai C, Xu Y, Gan Q, Cheng J. SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. J Gynecol Oncol. 2024;35(6):e79. https:\/\/doi.org\/10.3802\/jgo.2024.35.e79. Epub 2024 Mar 29. PMID: 38606823; PMCID: PMC11543254.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"2772_CR34","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41418-024-01399-y","volume":"32","author":"H Lingel","year":"2025","unstructured":"Lingel H, Fischer L, Remstedt S, Kuropka B, Philipsen L, Han I, Sander JE, Freund C, Arra A, Brunner-Weinzierl MC. SLAMF7 (CD319) on activated CD8+ T cells transduces environmental cues to initiate cytotoxic effector cell responses. Cell Death Differ. 2025;32(3):561\u201372. https:\/\/doi.org\/10.1038\/s41418-024-01399-y. Epub 2024 Oct 10. PMID: 39390117; PMCID: PMC11893764.","journal-title":"Cell Death Differ"},{"issue":"21","key":"2772_CR35","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1038\/s41388-019-0706-9","volume":"38","author":"M Fischer","year":"2019","unstructured":"Fischer M. Conservation and divergence of the p53 gene regulatory network between mice and humans. Oncogene. 2019;38(21):4095\u2013109. https:\/\/doi.org\/10.1038\/s41388-019-0706-9. Epub 2019 Feb 1. PMID: 30710145; PMCID: PMC6755996.","journal-title":"Oncogene"},{"key":"2772_CR36","doi-asserted-by":"publisher","unstructured":"Han EH, Cho SH, Lee SN, Cho MY, Lee H, Lee SY, Ngoc Thi Tran C, Park HS, Min JY, Kim HM, Park MS, Kim TD, Lim YT, Hong KS. 3D Scaffold-Based Culture System Enhances Preclinical Evaluation of Natural Killer Cell Therapy in A549 Lung Cancer Cells. ACS Appl Bio Mater. 2024;7(11):7194\u20137206. https:\/\/doi.org\/10.1021\/acsabm.4c00800. Epub 2024 Oct 11. PMID: 39392900.","DOI":"10.1021\/acsabm.4c00800"},{"key":"2772_CR37","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3389\/fimmu","volume":"8","author":"A Zingoni","year":"2017","unstructured":"Zingoni A, Fionda C, Borrelli C, Cippitelli M, Santoni A, Soriani A. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance. Front Immunol. 2017;8:1194. https:\/\/doi.org\/10.3389\/fimmu.","journal-title":"Front Immunol"},{"issue":"31","key":"2772_CR38","doi-asserted-by":"publisher","first-page":"49509","DOI":"10.18632\/oncotarget.10375","volume":"7","author":"M Ke","year":"2016","unstructured":"Ke M, Wang H, Zhou Y, Li J, Liu Y, Zhang M, Dou J, Xi T, Shen B, Zhou C. SEP enhanced the antitumor activity of 5-fluorouracil by upregulating NKG2D\/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget. 2016;7(31):49509\u201326. https:\/\/doi.org\/10.18632\/oncotarget.10375. PMID: 27385218; PMCID: PMC5226525.","journal-title":"Oncotarget"},{"issue":"50","key":"2772_CR39","doi-asserted-by":"publisher","first-page":"29964","DOI":"10.1074\/jbc.M115.674010","volume":"290","author":"G Cao","year":"2015","unstructured":"Cao G, Wang J, Zheng X, Wei H, Tian Z, Sun R. Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Upregulating NKp30 Ligand B7-H6. J Biol Chem. 2015;290(50):29964\u201373. https:\/\/doi.org\/10.1074\/jbc.M115.674010. Epub 2015 Oct 15. PMID: 26472927; PMCID: PMC4705966.","journal-title":"J Biol Chem"},{"key":"2772_CR40","doi-asserted-by":"publisher","first-page":"109552","DOI":"10.1016\/j.cellsig.2020.109552","volume":"69","author":"M Krze\u015bniak","year":"2020","unstructured":"Krze\u015bniak M, Zajkowicz A, Gdowicz-K\u0142osok A, G\u0142owala-Kosi\u0144ska M, \u0141asut-Szyszka B, Rusin M. Synergistic activation of p53 by actinomycin D and nutlin-3a is associated with the upregulation of crucial regulators and effectors of innate immunity. Cell Signal. 2020;69:109552. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109552. Epub 2020 Feb 4. PMID: 32032660; PMCID: PMC7126238.","journal-title":"Cell Signal"},{"key":"2772_CR41","doi-asserted-by":"publisher","unstructured":"Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249(4971):912-5. https:\/\/doi.org\/10.1126\/science.2144057. PMID: 2144057.","DOI":"10.1126\/science.2144057"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02772-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02772-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:24:00Z","timestamp":1781637840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02772-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2772"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02772-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Researchers received approval from the Bioethics Committee of the Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Gliwice Branch, to conduct experiments using cells from donor blood. Resolution No. KB\/430\u2009\u2212\u200929\/23.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}